
Transitioning to All-Oral AML Therapy: Prior Authorization Pearls and Copay Timing
Starting prior authorization before treatment begins, anticipating end-of-year deductible resets, and persisting through appeals can determine whether patients transition smoothly to oral AML therapy.
Episodes in this series

"Transitioning to All-Oral AML Therapy: Prior Authorization Pearls and Copay Timing" takes up the practical question of moving stable patients from intravenous to oral regimens.
Dr. Mahmoudjafari asks Dr. Murthy how he bridges patients from venetoclax plus intravenous hypomethylating agents to an all-oral regimen. Dr. Murthy says the most important factor is the right patient, motivated and able to understand the regimen. Groundwork begins in the hospital, where patients typically stay five to seven days. He first secures venetoclax and antifungal approvals and checks the patient's copay. He confirms parenteral hypomethylating agent doses are covered before submitting the oral authorization, so earlier approvals are not jeopardized. The outpatient pharmacist then manages the authorization after discharge. Response is assessed after cycle 1, but he transitions approved patients even if they are not yet in remission. He also warns of an end-of-year effect. A patient diagnosed in October may pay a high copay in November and December, then face a reset deductible in January.
Dr. Zeidan's top pearl is starting prior authorization early. He has seen teams realize on day 6 or 7 of azacitidine that the process never began. He recommends submitting before treatment starts, since the approval can simply go unused if plans change. His institution keeps a small supply to start therapy while outpatient supply is secured. Patients should not begin a drug they cannot continue at home. He sometimes asks patients to call insurers directly, alongside appeal letters and peer-to-peer reviews. Persistence usually succeeds, though he suspects the barriers are designed to discourage it. Copay foundations can help, but $2,000 can be impossible. He finds it saddest when patients choose seven days of infusion visits because they cannot afford oral therapy, which costs insurers more. Dr. Mahmoudjafari highlights template letters, AI-assisted appeals, and specialized pharmacy technicians, while noting some payers still do not treat leukemia as urgent.
In "Medicare Part D Redesign, Oral Chemotherapy Parity, and AML Treatment Costs," the panel will unpack Medicare Part D changes, oral chemotherapy parity, and provider incentives.
Related to this article








